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        The search of understanding the interaction of self-assembling 
nanostructures with proteins in biological environments is leading to the rapid 
development of key applications, including improved drug delivery systems with 
long retention time, and the reduced of nonspecific protein adsorbance of 
nanoparticles with tuned surface charges. In this work, the self-assembly and the 
behavior of drug amphiphiles with different charges in the presence of proteins were 
studied. These prodrug molecules of different surface chemistries are able to assemble 
into tubular nanostructures in aqueous solution with a similar range of critical micelle 
concentration(CMC). Among all these drug amphiphiles, non-ionic peptide-drug 
conjugates exhibit the strongest stability in FBS and human serum while cationic 
molecules immediately precipitated out in biological environments and other 
charged nanostructures showed unobvious degradation after two weeks in the 
presence of protein. We believe these findings build foundation to further study 
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1. Introduction  
                 The design of peptide-drug conjugates was originally intended to take 
advantage of short hydrophilic peptides in order to enhance the solubility and to provide 
additional functionality, such as the use of cell-penetrating peptides and tumor-
targeting peptides [1-5]. However, the conjugation of hydrophobic drugs with a low 
molecular weight and hydrophilic peptide segments can generate overall ampiphilicity, 
leading to a tendency for self-aggregation in aqueous media. This unintentional 
conjugation-induced assembly is now receiving rapidly growing interest in the drug 
delivery community. A class of self-assembling peptide-drug conjugated was recently 
developed in a way to functionally mimic protein-drug conjugated, termed “drug 
amphiphiles” (DAs), formed by the covalent conjugation of anticancer drugs to 
rationally designed peptides via a biodegradable linker [7-12]. 
1.1 Supramolecular hydrogels formed by self-assembling drug amphiphiles 
                Hydrogels, three dimensional polymer or supramolecular polymer networks, 
are an important class of biomaterials for drug delivery due to their sustained drug 
release capabilities. Early phase of the research in this field focused on polymer-based 
hydrogels formed by chemical cross-linking[13-18]. A large amount of cross-linking 
methods have been adapted for hydrogel synthesis and have received extensive 
attention[19-23]. However, the initiators utilized for hydrogel formation are potentially 
toxic and need to be removed afterwards. The another obstacle is the degradation of 
these covalently linked hydrogels in a biological setting, although there have been some 
novel methods to address this issue, such as incorporating enzymatically degradable or 
hydrolysable linkages into the systems[24-33].  Hydrogels fabricated by physical 
entanglement have receive increasing attention[34-37], especially in context of peptide 
assembly. The existing non-covalent interactions such as van der Waals, hydrogel 
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bonds, electrostatic interactions, metal-ligand interactions, host-guest recognition, and 
other types of enthalpic contribution result in the formation of these kind of 
hydrogels[34-37] (Fig. 1A). In addition, the gelation process is often reversible and can 
experience a repetitive transition from solution to gel and gel to solution by alternating 
the solution pH, ionic strength, or temperature (Fig. 1B). 
Fig. 1 Schematic illustration of (A) the interaction mechanisms of forming chemically 
and physically crosslinked polymeric hydrogels: covalent bond, electraostatic 
interaction, hydrogen bond, and host-guest or metal-ligand interaction, (B)assembly of 
peptidic monomers into filamentous assemblies that entangle further into 
supramolecular hydrogels (Reprinted with permission from Ref. [57]; Copyright (2017) 
Chinese Journal of Polymer Science). 
 
                 Small molecule peptides or rationally designed peptide derivatives often sever 
as peptide-based gelators which are prone to assemble into filamentous nanostructures 
in aqueous solutions [10-11,35,38]. Both molecular and intermolecular interactions at 
multiple length scales result in gelation. The directional hydrogen bonding is most 
essential interaction that lead to the association of peptidic units into one-dimensional 
(1D) objects among other types of entropic and enthalpic contributions, like 
hydrophobic forces, electrostatic interactions, and π - π interactions. Because of the 
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supramolecular nature, changes in temperature, pH, ionic strength or the presence of 
other molecules can successfully trigger the formation of supramolecular hydrogels 
(Fig. 1B). Peptide-based hydrogels have receiving rapidly growing interest recently due 
to their obvious merits---inherent biodegradability, biocompatibility and the ability to 
interact with biology.  Peptides with a small molecular weight can be easily synthesized 
using solid-phase peptide synthesis techniques and purified with high-performance 
liquid chromatography (HPLC). Due to the chemical and structural diversity of amino 
acids allowing a great variety of design parameters, the mechanical, physicochemical, 
and biological properties of the resulting gels can be easily tuned. Peptide based 
hydrogel systems can be divided by four major classes: unconjugated small molecule 
native peptides [39-40], peptide amphiphiles [41-43], aromatic peptides [34,44,45] and 
drug amphiphiles [46-53]. In this thesis, I focus on the supramolecular hydrogels 
formed by drug amphiphiles. 
                   Cui and co-workers designed a type of self-assembling peptide drug 
conjugates in a way to functionally mimic protein-drug conjugates [54]. These 
conjugates are formed by anticancer drugs and a rationally designed peptide which, due 
to the biological function and assembly potential of short peptides, are able to self-
assemble into high-aspect-ratio filamentous structures in aqueous solution, further 
forming self-supporting hydrogels. In addition, alternating the conjugated drug or 
optimizing biologically active peptide sequences results in easy tuning of the overall 
property/functionality of these filaments, providing a novel platform for effective 
cancer treatment.  
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Fig.2 The design of one-component theranostic hydrogels: (A) Design and chemical 
structure of Pem-FFEE DA; (B) Cartoon illustration of self-assembly of DAs into 
nanofibers and entanglement of fibers into hydrogels;(C) Cryo-TEM image of fibers 
formed by Pem-FFEE and optical picture of Pem-FFEE hydrogel; (D) In vitro CEST 
imaging of Pem-FFEE hydrogels with free Pem and C12-FE as controls (Reprinted 
with permission from Ref. [46]; Copyright (2017) American Chemical Society) 
 
                   Lock et al. recently reported a supramolecular strategy to conjugate an 
anticancer drug, Pemetrexed(Pem), to a supramolecular hydrogelator with inherent 
chemical exchange saturation transfer(CEST) MRI signals [46]. A Pem molecule was 
conjugated onto a short peptide sequence containing two glutamic acids and two 
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phenylalanines. In their design, Pem consisting aromatic amines and secondary amines 
in its chemical structure, serving as both an anticancer drug and a noninvasive MRI 
contrast agent. The two hydrophilic negative charged glutamic acids were incorporating 
to increase the water solubility of hydrophobic Pem drug. The π - π interactions from 
two aromatic phenylalanines promote the self-assembly of the resulting drug 
amphiphiles. This rationally designed PemFE drug amphiphiles are capable of 
associating into filamentous nanostructures and further entangle into a 3D network to 
fabricate self-supportive hydrogels(Fig 2B and 2C). They found incorporating of two 
phenylalanine significantly improving the potential of prodrug molecules to form 
supramolecular filamentous structures and hydrogels. They also found the location, 
distribution, recovery, and drug release of the injected PemFE drug amphiphiles can be 
detected by CEST MRI in a mouse glioma model.  In this study, a highly novel strategy 
to develop metal-free, MRI-guided theranostic supramolecular hydrogel delivery 
platform as a safer way for imaging-guided cancer therapy was shown.  
1.2 Supramolecular nanostructures formed by drug amphiphiles  
                   The effective treatment of both primary and secondary (metastatic) cancers 
requires  the systemic delivery of drugsto ensure exposure of all cancer sites to the 
anticancer agents. Molecular hydrogels have many merits for local delivery and 
treatment of the primary tumor but cannot efficiently affect any metastatic tumors that 
may have formed prior to treatment. A nanostructure-based strategy to this issue is the 
covalent modification of drugs in such a way as to form discrete nanostructures that can 
remain soluble without further aggregation of nanostructures. These PDCs, termed drug 
amphiphiles (DAs), are formed by covalently conjugating one or more anticancer drugs 
to a rationally designed/chosen peptide through a biodegradable linker [7-12].   
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                 Cui et al, reported the supramolecular strategy enabling the direct assembly 
of CPT DAs into discrete, stable and well-defined nanostructures with a high and 
quantitative drug loading [54]. Due to the branching point on the two amine functional 
amino acid lysine, conjugation of one, two or four CPT molecules can be achieved by 
attaching cysteine, resulting in fixed drug loadings of 23%,31% and 38% [Fig 3].   
Fig.3 Rational design of self-assembling drug amphiphiles. Self-assembling CPT-Tau 
conjugates with different CPT units. These drug amphiphiles do not have any dispersity 
in molecular weight and can be purified by HPLC (Reprinted with permission from Ref. 
[54]; Copyright (2013) American Chemical Society) 
 
                   The morphologies of the nanostructures also changed from nanofibers to 
nanotubes with the change of drug content. In addition, stability of these nano-sized 
assemblies formed by these drug amphiphiles is rather strong. Only when the 
concentration decrease to the nano-molar range by dilution, the dissociation occurred. 
That may result from the increasing hydrophobicity in combination with possible π–π 
associative interactions among the CPT units.  CPT release can be achieved by adding 
the cancer-relevant reducing agent GSH. 
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                    Su et al. recently reported a supramolecular platform of self-assembling 
prodrugs (SAPDs) that are able to associate into filamentous nanostructure in aqueous 
solution [55]. In their molecular design,  two CPT molecules were conjugated to three 
different types of short hydrophilic peptide sequences to generate three SAPDs, 
including dCPT-K2 , dCPT-OEG5 -K2 and dCPT-Sup35-K2 ,which all are capable of 
self-assembling into high-aspect-ratio one-dimensional nanostructures. However the 
internal molecular packing of the prodrug building units is different. dCPT-K 2 and 
dCPT-OEG 5 -K 2   associated into nanotubes with a hollow center because they do not 
possess a  β -sheet-forming peptide sequence, while dCPT-Sup35-K 2 with the β -sheet-
forming peptide sequence in the middle assembled into core-shell nanofibers. Strong  π 
- π interactions between CPT units dominate the formation of nanotubes and the lack 
of the strong, ordered intermolecular hydrogen bonding from Sup35 moieties  afforded 
for a higher degree of packing between the CPT units into tubular structures. The 
incorporation of a β -sheet-forming peptide sequence may result in the formation of the 
nanotubes because the β-sheet-forming peptide sequence demonstrates the arrangement 
of intermolecular hydrogen bonding.  They also found that nanotubes were much more 
stable than nanofibers. Additionally, they found these SAPDs possess a comparable 
efficacy against primary brain cancer cells over the free CPT.  Their findings support 
that π - π interactions could influence the formation of one-dimensional filaments. Due 
to this platform technology of self-assembling high potent long filaments, rational 
design of supramolecular prodrug-based hydrogels for local cancer chemotherapy can 
rapidly be developed. 
                   Ma et al. recently showed a follow-up reports about a self-assembling 
hybrid prodrug system containing both a CPT and a capecitabine (Cap) analogue (Fig.4) 
[56]. They found that assembled morphology of prodrugs and nanostructure stability 
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can be strongly influenced by the chemical structure of anticancer drug.  The 
nanostructures varied from long core-shell nanofibers to long filaments then to 
spherical particles with decreasing the number of CPT molecules. They also found that 
CPT-Cap filaments exhibited a synergistic effect and obviously improved potency 
against three esophageal adenocarcinoma cell lines over two homo-prodrugs and free 
parent drugs. 
                This example demonstrated integration of two structurally distinct drugs into 
a single self-assembling hybrid prodrug that provides strategy of fabricated self-
deliverable, one-dimensional filaments as excellent candidates fir hydrogel. 
 
Fig. 4 Chemical structure of dCPT-Sup35, CPT-Cap-Sup35 and dCap-Sup35 and 
illustration of their corresponding assembled nanostructures and TEM images of three 







1.3 Stability of self-assembling drug amphiphiles in biologic environments 
                   The surface of nanosized materials possess higher free energy than the bulk 
material itself, indicating that surface of nanoparticles will progressively and 
selectively absorb biomolecules when they contact with complex biological fluids [58-
61]. Adsorption of proteins form physiological fluids to nanocarriers results in the 
formation of a protein shell. This rapidly forming protein corona is responsible for the 
biological fate of nanocarriers [62-65]. Poly-(ethylene glycol) is widely used to reduce 
any non-specific protein adsorption and PEGylated drugs and nanovehicles exhibit 
longer blood half-lives and less non-specific cellular uptake. For surfaces, PEGlation is 
also used to reduce protein adsorption [66-70]. This feature is always called “stealthy 
effect”, which can be explained by the high level of hydration of the hydrophilic 
polyether, preventing protein adsorption on typically hydrophobic polymer surfaces by 
steric repulsion [71-74]. So in this thesis , we want to study weather OEG, the monomer 
of PEG, can reduce protein adsorption of self-assembling nanostructures and 
subsequently incress the nanostructure stability in biological environments compared 





2. Materials and Methods 
2.1 Synthesis and molecular characterization 
2.1.1 Materials 
         Fmoc amino acids (except Fmoc-Lys(Fmoc)-OH) and coupling reagents 
(HBTU) were purchased from Advanced Automated Peptide Protein Technologies 
(AAPPTEC, Louisville, KY, USA). Rink aminde MBHA resin and 
Fmoc-Lys(Fmoc)-OH were purchased from Novabiochem(San Diego, CA, USA). 
Camptothecin was obtained from AvaChem Scientific (San Antonio, TX, USA) and 
all other reagents were purchased from Sigma-Aldrich (St. Louis, MO) or VWR 
(Radnor, PA, USA). 
         RP-HPLC was performed on a Varian Prostar Model 325 HPLC (Agilent 
Technologies, Santa Clara, CA, USA) with a fraction collector. Preparative 
separations were performed using a Varian PLRP-S column (100 Å, 10 μm, 150 
mm×25 mm), while analytical HPLC utilized a Varian Pursuit CRs C18 column (5 μm, 
150 mm×4.6 mm). The mobile phase was acidic solutions (water and acetonitrile 
containing 0.1% v/v TFA). Purified target molecules were lyophilized using a 
FreeZone -105℃ 4.5L freeze dryer (Labconca, Kansas City, MO). ESI-MS mass 
spectrometric data for characterization was obtained using a Finnigan LDQ Deca 
ion-trap mass spectrometer (Thermo-Finnigan, San Jose, CA).  
2.1.2 Peptide Synthesis 
         All peptide conjugates, (Ac-Cys)2KK2 (dCys-K2), (Ac-Cys)2KE2 
(dCys-E2), (Ac-Cys)2K(OEG5)2 (dCys-(OEG5)2), (Ac-Cys)2KKE (dCys-KE) and 
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(Ac-Cys)2KEK (dCys-EK), here were manually synthesized on the Rink Amide 
MBHA resins with the scale of 0.25 mmole by utilizing standard 
9-fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis techniques. Fmoc 
deprotections were performed using 20% 4-methylpiperidine in DMF solution for 15 
minutes, repeating once. The amino acid coupling cycle was followed by adding a 
mixture of Fmoc-amino acids, HBTU and DIEA at a ratio of 4:4:6 relative to resin in 
DMF for 2 h. The conjugation of Fmoc-NH-OEG5-Propionic was performed using the 
same protocols as amino acids coupling. The branching point was realized by adding 
Fmoc-Lys(Fmoc)-OH to generate two amino groups before the coupling of 
Fmoc-Cys(Trt)-OH. Acetylation was performed at N-terminus of amino acids 
utilizing a 20% acetic anhydride in DMF solution with 100 μL DIEA for 15 min, 
repeated twice. In all cases, reactions were monitored by the ninhydrin test (Anaspec 
Inc., Fremont, CA) for free amines. All completed peptides were cleaved from the 
Rink resins using standard cleavage solution of TFA/TIS/H2O (92.5:5:2.5) for 3 h. 
Excess TFA was removed by air blow and the remaining peptide solution was 
precipitated in cold diethyl ether to obtain crude products, which were 
phase-separated from diethyl ether using centrifugation technique (5900 rpm for 4 
min) and dried under vacuum overnight. 
2.1.3 Peptide Purification 
        Peptide purification was achieved on RP-HPLC using a Varian ProStar 
model 325 HPLC (Agilent Technologies, Santa Clara, CA, USA) equipped with a 
fraction collector. All crude peptides were dissolved in 20 mL of 0.1% v/v TFA and 
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purification run was carried out with a 10 mL injection. A water/acetonitrile gradient 
10%-90% was ran for 30 minutes containing 0.1% v/v TFA at a flow rate of 20 
mL/min. The 220 nm signal from UV-Vis detector was used to trigger the fraction 
collector for preparative RP-HPLC. Collected fractions were identified by ESI-MS 
(LDQ Deca ion-trap mass spectrometer, Thermo Finnigan, San Jose, CA) and the 
ones containing desired products were lyophilized (FreeZone -150 ℃ 4.5L freeze 
dryer, Labconco, Kansas City, MO) and stored in -30℃ fridge.  
2.1.4 Electrospray Ionization-Mass Spectra (ESI-MS) 
        ESI mass spectra were acquired on a Finnigan LDQ Deca ion-trap mass 
spectrometer equipped with an electrospray ionization source (Thermo Finnigan, San 
Jose, CA). Samples were in DI water with 5% of acetonitrile containing 0.1% v/v 
NH4OH and introduced into the instrument at a rate of 10 L/min using a syringe 
pump via a silica capillary line. The heated capillary temperature was 250 ℃ and the 
spray voltage was 5 kV. 
2.1.5 Analytical HPLC Characterization 
        Analytical RP-HPLC was performed using a Varian polymeric column 
(PLRP-S, 100 Å, 10 μm, 150 mm× 4.6 mm) with 20 μL injection volume. A 
water/acetonitrile gradient 15%-85% was run for 20 minutes containing 0.1% v/v TFA 
at a flow rate of 1 mL/min.  
2.1.6 Drug Amphiphile Synthesis and Characterization 
        The synthesis of drug amphiphiles was achieved by mixing CPT-etcSS-Pyr 
and the corresponding crude peptides in 2 mL of N2-purged DMSO with a molar ratio 
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of 2:1 and allowing them to react for 5 days. The mixture was diluted to 10 mL in 
acetonitrile/water with 0.1% v/v TFA and purified by preparative RP-HPLC using a 
Varian ProStar model 325 HPLC (Agilent Technologies, Santa Clara, CA, USA) 
equipped with a fraction collector. Separations were carried out on a Varian PLRP-S 
column (100 Å, 10 μm, 150 mm×25 mm ) monitoring at 370 nm. Collected fractions 
were probed by ESI-MS (LDQ Deca ion-trap mass spectrometer, Thermo Finnigan, 
USA), and the fractions with targeting molecules were collected, concentrated and 
lyophilized on a FreeZone -105 ℃ 4.5 L freeze dryer (Labconco, Kansas City, MO, 
USA). The powders obtained were then re-dissolved, calibrated and aliquoted into 
cyro-vials before re-lyophilization. 
2.1.7 Concentration calibration  
        The concentrations of purified drug amphiphiles were calibrated by 
analyzing the reduced product free CPT from drug amphiphiles. Briefly, all samples 
were dissolved in MeCN/H2O (1:1) to obtain the stock solutions. 5 μL of the stock 
solution was then diluted to 20 μL by addition of 15 μL MeCN/H2O (1:1) and mixed 
with 20 μL of 1 M aqueous TCEP for 1 h by periodic vortexing to allow disulfide 
bond cleavage and obtain free CPT from drug amphiphiles. To measure the area of the 
peak resulting from free CPT at 370 nm, 30 μL of solution was then injected into the 
HPLC. The concentration of CPT was obtained by comparing the area of the peak 
from TCEP-treated solution with the standard calibration of CPT. The drug 
amphiphile concentration was further calculated by the applied dilutions and the 
number of CPT molecules. The stock solution was diluted to 400 μM according to the 
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Fig. 5 Schematic illustration for synthesis of drug amphiphiles. (A) Synthetic routes 
of peptide segments dCys-K2 and dCys-OEG2 using standard Fmoc solid phase 
peptide techniques (dCys-E2, dCys-KE and dCys-EK use the similar protocols as 
dCys-K2). (B) Synthesis of functional drug amphiphiles by mixing peptide segments 





2.2 Self-assembly characterization 
2.2.1 Transmission electron microscopy (TEM) imaging  
       200 μM solutions of corresponding samples in 1×DPBS were prepared by 
directly dissolving respective lyophilized powders, and allowed to age overnight. 
TEM samples were prepared by depositing 10 μL of the respective solution onto a 
carbon-coated copper grid (Electron Microscopy Services, Hatfield, PA, USA), 
wicking away the excess solution with a small piece of filter paper. 10 μL of a 2 wt% 
uranyl acetate aqueous solution was then deposited on the surface and after 30 
seconds the excess solution was removed as above to leave a very thin layer. The 
sample grid was then air-dried at room temperature at least 3 hours prior to imaging. 
Bright-field TEM imaging was performed at an acceleration voltage of 100 kV on the 
Tecnai 12 TWIN transmission electron microscopy instrument equipped with 16 bit 
2K×2K FEI Eagle bottom mount camera (FEI, Hillsboro, OR) and SIS Megaview III 
wide-angle CCD camera.  
2.2.2 Cryogenic TEM imaging  
         Cryo-TEM imaging was performed at a higher concentration of 800 μM 
compared with 200 μM in conventional TEM imaging, since higher concentration 
allows more rapid visualization of the structures and reduces possibility of damage to 
vitreous ice film caused by the electron beam during imaging. 6 μL of the appropriate 
solution was dropped onto a lacey carbon film supported TEM copper grid (Electron 
Microscopy Services, Hatfield, PA, USA). All the TEM grids used for cryo-TEM 
imaging were treated with plasma air to render the lacey carbon film hydrophilic. A 
16 
 
thin film of the sample solution was produced using the Vitrobot with a controlled 
humidity chamber (FEI). After loading of the sample solution, the lacey carbon grid 
was blotted using preset parameters and plunged instantly into a liquid ethane 
reservoir precooled by liquid nitrogen. The vitrified samples were then transferred to 
a cryo-holder and cryo-transfer stage that was cooled by liquid nitrogen. To prevent 
sublimation of vitreous water, the cryo-holder temperature was maintained below 
-170°C during the imaging process. All images were recorded by a 16 bit 2K × 2K 
FEI Eagle bottom mount camera. 
2.2.3 Circular dichroism 
        CD spectra were recorded on a Jasco J-710 spectropolarimeter (JASCO, 
Easton, MD) from 190 nm to 480 nm using a 1 mm (for 100 μM and 50 μM) or 10 
mm (for 12.5 μM and 3.125 μM) path length quartz UV-Vis absorption cell (Thermo 
Fisher Scientific, Pittsburgh, PA, USA). Background spectra of the solvents were 
obtained and subtracted from the sample spectra. The mean residue ellipticity [θ] was 





Where θ is the acquired ellipticity in deg, C is the concentration of the drug 
amphiphiles calibrated by analyzing the reduced product free CPT, l is the light path 
length of the quarts UV-Vis absorption cell, and n is the number of amino acid 
residues. 
2.2.4 Determination of critical micellization concentration (CMC) 
       The determination of CMC values were performed according to the modified 
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protocol of a reported work. Identical volume of the Nile Red solution which was 
initially prepared by dissolving the dye in acetone was loaded in centrifuge tubes. Dry 
mass of Nile Red was yielded by solvent evaporation under room temperature. 
Various concentrations of the drug amphiphile solution were prepared in H2O or PBS, 
and then added into the centrifuge tubes with same amount of Nile Red solids. These 
mixtures of Nile Red and drug amphiphiles after vortexing were incubated in the dark 
at room temperature overnight to assume equilibrium. Fluorescent spectra of Nile Red 
were detected by a Fluorolog fluorometer (Jobin Yvon, Edison, NJ) with fixed 
excitation wavelength at 560 nm; emission spectra were monitored within 580-720 
nm. The ratios of the emission intensity at 635nm (near the emission maximum when 
Nile Red was encapsulated in the hydrophobic environments) to that at 660 nm (the 
weak emission maximum in aqueous conditions) were then plotted against the drug 
amphiphiles concentrations. The surge in intensity ration (I635/I660) reveals the dye 
being encapsulated into the hydrophobic environments in assembled structures 
because the Nile Red was strongly quenched in aqueous conditions, while this 
transition occurs as the incubated drug amphiphiles exceed their CMC values. The 
CMC values were obtained by calculating the crossover point of the ratio curve 
plotted against the drug amphiphile concentrations before/after the intensity surge.  
 
2.2.5 Physical stability of five different charged nanotubes 
        We next investigated the stability of five different charged nanotubes upon 
dilution in cell medium using CD spectrometer. To get rid of the influence of phenol 
red in spectrometer, we used DMEM (phenol red free, Mediatech) containing 10% 
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fetal bovine serum (FBS, Invitrogen) and 1% antibiotics (Invitrogen) as cell medium 
solution. The stock solutions of these molecules were prepared at the concentration of 
1 mM in water and aged overnight. The aged solution was diluted to 200 μM with cell 
medium. After that, solutions containing 200 μM of these nanotubes in cell medium 
were further diluted to 100 μM, 50 μM, 25 μM, 10 μM and 5μM. All the diluted 
solutions were incubated for another two days before CD measurement. All the CD 
spectra were recorded from 300 to 480 nm using a 1 mm (for 200 μM, 100 μM and 50 
μM) or 10 mm (for 25 μM, 10 μM and 5 μM) path length quartz cell. The spectra 
were collected and normalized from ellipticity (mdeg) to molar ellipticity 
(deg· cm2 ·dmol−1). No significant changes were observed from the normalized 
curves, indicating no obvious disassociation of the self-assembled nanotubular 
structures at the concentration above 5 µM. In addition, the solution of nanotube in 
cell medium remained clear after one week, suggesting no obvious aggregation of 
nanotubes in cell medium. 
 
2.2.6 UV-Visible spectroscopy 
 
        The solutions of these different drug amphiphiles in DMEM with 10% FBS 
and human serum at concentration 200 µM were measured using a UV-Visible double 
beam spectrophotometer (UV-1601 PC, Shimadzu, Japan; H14 grating UV) through 
optical resolution of 0.4 nm. Transparent degree measurements of these solution were 
obtained over wavelength of 200-600 nm at room temperature using quartz cuvettes 
(1 mm path length). We carried out transparent degree measurements of the same 
solutions during two weeks at different time point to study the stability of these drug 
19 
 
amphiphiles in DMEM with 10% FBS or human serum. The cuvettes were cleaned 






























3. Results and Discussion 
3.1 Synthesis of self-assembling different charged drug amphiphiles 
          The synthesis was realized in a modular and eficient fashion utilizing 
established synthetic strategies. Briefly, the diferent charged peptide segments with 
two N-terminal cysteine residues (dCys-K2, dCys-E2 , dCys-OEG2, dCys-KE, dCys-EK) 
were first synthesized using standard Fmoc solid-phase synthesis protocols. To 
conjugate CPTs onto the peptide, the disulfide formation reaction was then performed 
in nitrogen-purged DMSO as reported previously. The molecular masses of the final 
products were confirmed using electrospray ionization mass spectroscopy, and their 








 Fig. 6 RP-HPLC and ESI-MS spectrum of dCPT-K2 (a). The peaks at 796.97 and 
1592.55 corespond to [M+H]2+ and [M+H]+, respectively. RP-HPLC and ESI-MS 
spectrum of dCPT-E2 (b). The peaks at 819.64and1616.37 corespond to [M+Na]2+ 
and [M+Na]+, respectively. RP-HPLC and ESI-MS spectrum of dCPT-OEG2 (c). The 
peaks at 706.7 and 1059.4 corespond to [M+2H]2+ and [M+H]3+, respectively. RP-
HPLC and ESI-MS spectrum of dCPT-KE (d). The peaks at 798.48 and 1593.59 
corespond to [M+2H]2+ and [M+H]+, respectively. RP-HPLC and ESI-MS spectrum 
of dCPT-EK (e). The peaks at 819.45 and 1593.52 corespond to [M+Na]2+ and 
[M+H]+, respectively. 
 
3.2 Self-assembly of drug amphiphiles 
          The self-assembling molecules containing a bent-shaped aromatic segment 






project, we conjugated crescent-shaped anticancer drug, camptothecin (CPT) to 
hydrophilic peptide sequences to generate self-assembling prodrugs. The self-assembly 
of cationic prodrug, dCPT-K2, was initiated by dissolving the lyophilized molecules 
into deionized water. The regular TEM image showed that dCPT-K2 self-assembled 
into hollowed soft nanotubes in DI water at concentration 200 μM, after aged for 1 day 
at room temperature.  According to the diameter analysis of dCPT-K2 nanotubes 
obtained from the TEM image, their diameters are 8.3 nm. In addition, the lengths of 
these nanotubes are in micrometer range. Circular dichroism spectrum of dCPT-K2 at 
200 μM in aqueous solution (Figure) indicated the ordered chiral pack of internal 
aromatic CPT moieties. Two bisignate CD signals at 266 nm and 367 nm are due to 
strong exciton coupling between neighboring CPT aromatic rings. The strong positive 
signal centered at 389 nm is resulted from a positive chirality and a right-handed helical 
arrangement of the planate CPT units. The one-dimensionality of the nanotubes is 
further confirmed by the negative β-sheet signal at around 223 nm for peptide region. 
All these results reveal that cationic prodrug self-assembles into nanotubes with a 
monolayered pattern and strong π-π interaction resulting from bent-shaped CPT units 
is essential for tubular structure of the molecule. 
                      Assembled morphologies are able to be switched by altering the 
hydrophilic segments which leads to the changes in the crucial hydrophilic-lipophilic 
balance, electrostatic interactions and hydrogen bonding. Only when one of the 
interactions so strong to dominate the whole self-assembling process can same 
nanostructures be built with different self-assembling monomers. In this project, we 
envision that due to the strong packing of hydrophobic CPT moieties, the self-
assembling tubular morphologies of prodrugs will not be significantly changed by other 
small molecule functional hydrophilic segments. Conventional TEM images reflected 
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the one-dimensionality of those nanotubes with the emblematic dark centerlines. The 
length of these assembled aggregates are all up to micrometer scales and the diameters 
are in the range of 8.5-10.5 nm. Thus, anionic, zwitterionic, non-ionic prodrugs can also 
self-assemble into nanotubes at the same condition with cationic prodrug. In order to 
confirm the formation of the nanotubes, we further carried out the circular dichroism 
(CD) measurements of all these prodrugs at 200 μM. A strong negative signal at around 
223 nm was observed in five molecules, revealing the formation of β-sheet secondary 
structure of peptide segment in the self-assembled state, which consists with the one-
dimensionality of the nanotubes. Also the CD spectra show two bisignate CD centered 
at 266 and 367 nm due to strong exciton coupling between adjacent CPT aromatic rings, 
and a strong positive signal at 389 nm resulting from a positive chirality and a right-
handed helical arrangement of the planar CPTs. All these CD spectra reveal the packing 
of all assembled aggregates are in a similar fashion. Closer or looser packings of the 
building units influenced by the total amphiphilicity, electrostatic interaction as well as 
hydrogen bonding caused the CD intensity differences among those prodrugs.  
24 
 
Fig. 7 TEM images of dCPT-K2 (a), dCPT-E2(b),DCPT-OEG2 (c),dCPT-KE (d) and 
dCPT-EK(e) at a concentration of 200 uM in PBS and CD spectrum of these drug 
amphiphiles(f) 
         Critical micelization concentrations (CMC) of these drug amphiphiles with 






intensely fluoresces in hydrophobic core of nanostructure but is highly quenched and 
red-shifted in aqueous solution. Ploting the ratio of intensity at 635 nm (emission 
maximum of the encapsulated dye) to that at 660 nm (emission maximum in aqueous 
conditions) against the concentration of each drug amphiphile indicates the transition 
that occured when the molecule concentration surpass the CMC. No obvious 
diference was observed in calculated CMC values, within a range of 2-5 μM, of these 
diferent charged drug amphiphiles, indicating that surface charges of these assemblies 
have a minor impact on associating concentration values which are mainly due to the 
strong interaction of CPT moieties on the drug amphiphiles. 
Fig. 8 Calculated CMC values of dCPT-K2 (a), dCPT-E2(b), dCPT-OEG2 (c),dCPT-KE 
(d) and dCPT-EK(e) in PBS. 
 
         We also determined the critical micelization concentrations (CMC) of the 
nanotubular assemblies in DMEM, a standard cel culture medium, using same 
encapsulated-dye method. The CMC of the studied peptides was determined by 
incubating these molecules at various concentrations with a fixed content of Nile red. 
After ploting the ratio of intensity at 635 nm to that at 660 nm, we found the transition 




due to the reason that peptide concentration exceeded CMC (Fig. 8). These drug 
amphiphiles self-assembling in DMEM possess similar CMC range as them in PBS 
(Fig. 9). 
Fig. 9 Calculated CMC values of dCPT-K2 (a), dCPT-E2(b), dCPT-OEG2 (c),dCPT-
KE (d) and dCPT-EK(e) in DMEM. 
 
3.3 Stability of self-assembling nanostructures in the presence of proteins 
         Then we dissolved al drug amphiphiles solutions into DMEM with 10% 
FBS. Cationic drug amiphiphile, dCPT-K2, immediately precipitated out resulting from 
the surface positive charges which possess a strong tendency to unspecificaly bind with 
proteins in the FBS. The other solutions with a initiate transparent status were placed 
in room temperature over 2 weeks. Except non-ionic drug amphiphiles keep clear after 
two weeks, the other molecules, including ionic and zwiter-ionic drug amphiphiles 
showed a different degree of precipitation. Non-ionic nanostructures with OEG 
protected possess a reduced unspecific protein binding and showed a stronger stability 
among other drug amphiphile DMEM/FBS solutions. 






Fig. 10 Photos show the turbidity changes of drug amphiphiles with different surface 
charges over two weeks. Non-ionic molecules, dCPT-OEG2, remain clear even after 
two weeks. 
 
                 Transmission spectra of the molecules were further monitored by UV-VIS 
(Fig. 11). The results are consistent with the situation showed in photos over time. The 
transmission percentage of charged DAs significantly decreased in second week, 
revealing the solution of these molecules obviously became turbid after two weeks. But 










Fig. 11 The transmission spectra detected by UV-Vis showed dCPT-K2(a), dCPT-E2(b), 
dCPT-OEG2(c), dCPT-KE(d) and dCPT-EK(e) exhibited a diferent degree of 
transmission degree change over times 
 
         Because of the strong fluorescence of proteins in FBS, the emission spectra 
of Nile red failed to be detected. Thus CMC values of the drug amphiphiles in the 
presence of proteins are indirectly speculated by studying the initial concentration of 
interior CPT packing utilizing CD. The CD spectra of Cationic DA, dCPT-K2 in 
DMEM with 10% FBS solution were not obtained because of instant dCPT-K2 
precipitation in presence of proteins. When the concentration is above 5 um, a positive 
peak at around 380 nm atributed to the arangement of CPT in the assembled form 
becomes obvious, which means CPT molecules of drug amphiphiles started packing 
with each other at 5 uM, suggesting the aggregation of these DAs occured when 
concentration reach 5 uM which is similar with CMC values of these drug amphiphiles 
without proteins (Fig. 12). 
 
 




Fig. 12 The CD spectra of dCPT-E2(a), dCPT-OEG2(b), dCPT-KE (c)and dCPT-EK(d) 
with a wavelength range from 300 nm to 480 nm. Cryo-TEM images of the 
nanostructures of initial dCPT-OEG2 solution(e) and the solution after one month (f) 
at a concentration of 200 uM in DMEM with 10% FBS. 
 
                 According to the cryo-TEM images, the originate solution of non-ionic 
prodrugs self-assembled into nanotubes which is the same as the nanotubes formed by 
these prodrugs solution after one month. Because the OEG molecules in self-assembled 
drug amphiphiles reduce the non-specific protein adsoption, these nanotubes have a 
better stability (Fig. 12). To better understand the stability of drug amohiphiles , we 
replaced the FBS with human serum which can better mimic in-situ environments. After 
dissolving in PBS, these molecules were diluted by human serum. Cationic drug 
amphiphiles, dDPT-K2, are quickly crushed out, which is the same as dissolving these 
positive charged molecules in FBS. Then we investigated the turbidity of the other 
solutions using UV-Vis to monitor the transmission degree (Fig. 13). The results are 
consistent with the photo of all the solution, showing that non-ionic drug amphiphiles 
possessed a highest transmission degree. All these results revealed that these molecules 







Cryo-TEM was carried out in order to investigate the nanostructures of drug 
amphiphiles except cationic one. The differences between the charged nanotubes and 
the neutral nanotubes were obvious. The nanotubes formed by non-ionic drug 
amphiphiles are longer, better organized as well as possess a clearer margin than other 
nanotubes with aggregation of proteins leading to the vague margin of nanotubes. In 
addition, cryo-TEM images showed the intact and long nonatubes in the initial solution 
of dCPT-OEG2 and the solution after one month further demonstrated that 
nanostructures of self-assembling non-ionic drug amphiphiles can be stable longer in 
biological environments than other charged drug amphiphiles (Fig. 14).  
Fig. 13 Photos of the solution of dCPT-K2(a), dCPT-E2(b), dCPT-OEG2(c), dCPT-
KE(d) and dCPT-EK(e) in human serum. The transmission spectra of five different 








Fig. 14 Cryo-TEM images of dCPT-E2(a), dCPT-OEG2 (b),dCPT-KE (c) , dCPT-EK(d)  
and dCPT-OEG2 after one month at a concentration of 200 uM in PBS with 50% human 
serum.






In summary, all designed drug amphiphiles with different chages are able to self 
assemble into nanotubes at a same condition, indicating that the self-assembly 
behaviors of these drug amphiphiles are dominated by the strong π-π interaction of CPT 
moieties in assembled form instead of the carrying charges. In addition, different degree 
of protein adsorption lead to the variations of stability of drug amphiphiles with 
different charges. Among all the molecules, cationic conjugates exihibited weakest 
stability while non-ionic drug amphiphiles are able to stable longest in biological 
environments.  Thus, increasing the stability of drug amphiphile nanostructures in the 
precense of proteins can be achieved by incorporating OEG molecules into hydrophilic 
peptide sequences. We believe that this research provide a new platform for 
development of theranostic biodegradable nanostructures with a long retention time by 
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